The change is a landmark in transparency that puts Europe ahead of the
United States, according to critics of the $1 trillion-a-year global drugs
industry, who have long argued for full access to trial data.
Such information is a treasure trove for scientists wanting to test drug
company claims and potentially expose product deficiencies." Read more
See also
"Scientific Data: Open Access to Research Results Will Boost Europe's Innovation Capacity." Press release, European Commission, July 17, 2012.
